Stock screenerAll disclosures →
EDGAR →
LGND
Conviction 54HealthcareScan · Fri, Sep 25, 2026Ligand Pharmaceuticals Inc (LGND) closed at $301.55 (+0.84%) on Sep 25, 2026. Price is above its 50-day and above its 200-day moving average. RSI(14) 63, RS Rating 91, -6.5% from its 52-week high, +58.6% year to date. Sector: Healthcare · PHARMACEUTICAL PREPARATIONS.
LGND$301.55+0.84%
ResistanceSupportVol 14Insider sellCongress buyCongress sell2
Vol MA14 249.88K
Jun 29Jul 16Aug 4Aug 20Sep 9Sep 25
Price301.55
Change+0.84%
Gap+0.20%
Rel volume—
Avg volume226.28K
Avg $ vol65.17M
SMA 20287.52
SMA 50291.07
SMA 200238.72
Price vs 50+3.60%
Price vs 200+26.32%
MA stackbullish
50/200 cross—
Supertrendup · 274.57
RSI (14)63
MACD hist2.35
MACD crossbull · 4d
Stoch %K / %D89 / 88
ADX (14)17
+DI / −DI23 / 14
RSI divergence—
MACD divergenceBullish
ATR %2.93%
ADR %2.92%
52w high322.61
52w low166.76
From 52w high-6.53%
Above 52w low+80.83%
New 52w highNo
SqueezeOff
Bollinger width9.86%
%B1.00
Donchian pos89.04%
Donchian high305.34
Donchian low270.77
AVWAP (52w high)295.16
vs AVWAP high+2.16%
AVWAP (52w low)239.03
vs AVWAP low+26.15%
OBV trendFlat
Chaikin MF (20)0.16
Today vs 20d—
Avg vol (14d)249.74K
Avg vol (20d)226.28K
Avg $ vol (20d)65.17M
Market cap6.01B
RS Rating91 / 99
RS 3m (vs SPY)-6.48%
RS 6m (vs SPY)+28.47%
RS line new highNo
Trend template7/8
Technical rank91.6
1 week+6.37%
1 month+4.76%
3 months-0.67%
6 months+48.04%
1 year+78.47%
YTD+58.62%
P/E48.30
P/B6.21
P/S22.42
P/FCF122.92
EPS6.13
Div yield—
ROE12.86%
ROA5.69%
Debt/Eq1.16
Current31.18
EV/EBITDA82.00
Gross margin—
Net margin46.42%
Rev growth60.40%
EPS growth3186.63%
Price target356.29
Target upside18.15%
Analyst ratingBuy
Institutional129.05%
Ent. value6.13B
Revenue63.69M
Net income48.51M
Gross profit—
Free cash flow48.91M
IndustryPHARMACEUTICAL PREPARATIONS
ExchangeNasdaq
Shares out20.04M
Employees47
ListedFri, Nov 25, 1994
Free float18.87M
Float %95.9%
Short interest2.48M
Days to cover14.1d
Short volume63.5%
Squeeze score67 / 100
Next earnings—
EPS forecast—
Last EPS vs est$2.22 vs $1.34
Last surprise+65.7% beat
Setup gradeC
Conviction54 / 100
Pattern quality—
Tech rank91.6 / 100
Group rank50 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance307.89
Support273.19
Days since event—
Candle confirm—
Financials as of Tue, Jun 30, 2026 · quarterly.
Recent news
- Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 MillionYahoo Finance · Thu, Sep 24, 2026
- Sydnexis Announces Royalty Agreement with Ligand for Ryjunea®Yahoo Finance · Tue, Sep 22, 2026
- Ligand Acquires Royalty and Milestone Interest in Santen’s Ryjunea® from Sydnexis for $23 MillionYahoo Finance · Tue, Sep 22, 2026
Congress activity
Disclosed STOCK Act trades in LGND · 2 recent
Insider activity
SEC Form 4 transactions in LGND · open-market 1 sell
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Espinoza Octavio Chief Financial Officer · Common Stock · 2026-08-12 | Exercise | 16.18K | $855K | 2026-08-12 | 2026-08-14 |
Espinoza Octavio Chief Financial Officer · Common Stock · 2026-08-12 | Exercise | 2.07K | $145K | 2026-08-12 | 2026-08-14 |
Espinoza Octavio Chief Financial Officer · Common Stock · 2026-08-12 | Exercise | 2.87K | $160K | 2026-08-12 | 2026-08-14 |
Espinoza Octavio Chief Financial Officer · Common Stock · 2026-08-12 | Exercise | 7.17K | $410K | 2026-08-12 | 2026-08-14 |
Espinoza Octavio Chief Financial Officer · Common Stock · 2026-08-12 | Exercise | 3.35K | $230K | 2026-08-12 | 2026-08-14 |
Espinoza Octavio Chief Financial Officer · Common Stock · 2026-08-12 | Sell | 31.64K | $9.2M | 2026-08-12 | 2026-08-14 |
Espinoza Octavio Chief Financial Officer · Employee Stock Option (right to buy) · 2026-08-12 | Exercise | 2.87K | — | 2026-08-12 | 2026-08-14 |
Espinoza Octavio Chief Financial Officer · Employee Stock Option (right to buy) · 2026-08-12 | Exercise | 7.17K | — | 2026-08-12 | 2026-08-14 |
Espinoza Octavio Chief Financial Officer · Non-Qualified Stock Option (right to buy) · 2026-08-12 | Exercise | 16.18K | — | 2026-08-12 | 2026-08-14 |
Espinoza Octavio Chief Financial Officer · Non-Qualified Stock Option (right to buy) · 2026-08-12 | Exercise | 3.35K | — | 2026-08-12 | 2026-08-14 |
SEC filings
EDGAR filings in LGND · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.
Start free — 14-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.